Vero E6 cells are a subline of the Vero cell family, originally derived from the kidney of an African green monkey in 1962 at Chiba University in Japan. They are among the most widely used cell lines in virology and vaccine manufacturing because they carry a genetic defect that prevents them from producing interferon, one of the body’s main antiviral defense molecules. That quirk makes them exceptionally hospitable to viruses, which is exactly what researchers need when they want to grow, study, or test drugs against dangerous pathogens. The “E6” designation refers to a specific clone selected for particular properties, and this subline has become a workhorse for everything from isolating new viruses to producing vaccines at industrial scale.
Where Vero Cells Come From
The original Vero cell culture was started on March 27, 1962, when researchers at Chiba University took kidney tissue from an African green monkey (Chlorocebus species) and began growing it in the lab.1DNA Research. The Genome Landscape of the African Green Monkey Kidney-Derived Vero Cell Line After months of passaging, several continuous sub-lines were obtained, and one was chosen as the standard Vero cell line. Over the decades, additional sub-lines were derived for different purposes, and Vero E6 (also called Vero C1008) became one of the most prominent. The name “Vero” itself comes from an abbreviation of a Esperanto phrase meaning “truth,” reflecting the spirit of the Japanese research team that established it.
Today, Vero cells are maintained at major cell repositories around the world. Growing and maintaining them in a lab setting is relatively straightforward, following standard protocols for mammalian cell culture.2PubMed Central. Growth and maintenance of Vero cell lines Researchers can order authenticated stocks from repositories like the American Type Culture Collection (ATCC), which helps ensure that labs worldwide are working with cells that have a known, well-characterized genetic background.
The Interferon Deficiency That Makes Them So Useful
The single most important feature of Vero cells, and the reason they became a staple of virology labs, is their inability to produce type I interferon. In a normal cell, when a virus invades, the cell releases interferons to alert neighboring cells and trigger an immune response that slows viral replication. Vero cells cannot do this. Research dating back to the late 1970s showed that a clone of Vero cells was “totally unable to synthesize interferon,” and the authors proposed that the gene for interferon production was either defective or absent.3Microbiology Society / J Gen Virol. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production
Modern genomic studies have confirmed and clarified this. All Vero sublines share a large deletion on chromosome 12, which is exactly where type I interferon genes and certain tumor-suppressor gene clusters are located.4PubMed Central. Whole-Genome Sequencing of Vero E6 (VERO C1008) and Comparative Analysis of Four Vero Cell Sublines Without those genes, the cells have no way to mount an interferon-based defense when a virus enters. From a researcher’s perspective, this is a feature, not a bug. Viruses that would normally be fought off by interferon can replicate freely in Vero cells, making them easy to grow, observe, and experiment on.
How Vero E6 Differs from Other Vero Sublines
Not all Vero cells are the same. Over the years, multiple sublines have diverged genetically in subtle but meaningful ways. Vero E6 has a few distinguishing characteristics compared to its siblings like Vero CCL-81, Vero 76, and Vero JCRB0111. For instance, chromosome 21 is heavily rearranged in several other Vero sublines, but the copy number in Vero E6 is essentially normal except at the far end. Vero E6 also shows monosomy for the X chromosome, meaning it has only one copy instead of two.4PubMed Central. Whole-Genome Sequencing of Vero E6 (VERO C1008) and Comparative Analysis of Four Vero Cell Sublines Whether these chromosomal differences translate into practical differences in how well any given virus grows is something researchers evaluate virus by virus.
Broader genomic analyses of the Vero lineage have revealed the extent of change these cells have undergone during decades of culture. One study found the modal chromosome number in the parent Vero JCRB0111 line to be 59 rather than the expected 60, due to a fusion between two chromosomes, and identified multiple translocations, duplications, and deletions.5DNA Research. The Genome Landscape of the African Green Monkey Kidney-Derived Vero Cell Line Another analysis catalogued over 12 million small genetic variants and more than 7,000 large structural rearrangements compared to the wild African green monkey genome, with thousands of genes predicted to have lost their function.6npj Vaccines. Haplotype-resolved de novo assembly of the Vero cell line genome This level of genomic disruption is typical for cell lines that have been passaged continuously for decades, and it underscores why researchers need to be careful about which subline they use and how many times they passage it before experiments.
Why Vero E6 Cells Are a Favorite for Studying Dangerous Viruses
Vero E6 cells are susceptible to an impressive range of human and animal viruses. Their membrane carries hundreds of proteins, and proteomic studies have identified at least 17 known virus receptor proteins on their surface.7PubMed Central. Proteomic analysis of membrane proteins of vero cells: exploration of potential proteins responsible for virus entry That broad receptor profile, combined with the missing interferon response, makes them a go-to system for isolating and growing viruses that are difficult to culture elsewhere.
The COVID-19 pandemic put Vero E6 cells squarely in the spotlight. When the first U.S. case of SARS-CoV-2 was confirmed, the virus was isolated using Vero cell lines. Researchers found that the virus replicated to high levels in both Vero CCL-81 and Vero E6 cells without the need for trypsin, a digestive enzyme sometimes required to help viruses enter cells.8PubMed Central. Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient This made the early stages of pandemic research much faster. Studies comparing SARS-CoV-2 and the original SARS coronavirus used Vero E6 cells to analyze replication kinetics and the visible damage each virus caused to cells.9PubMed Central. SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology Animal experiments during the pandemic also relied on virus stocks prepared in Vero E6 cells, where the virus was passaged and then titrated to calculate the right dose for infection studies.10Nature Communications. Fatal COVID-19 pulmonary disease involves ferroptosis
Beyond coronaviruses, Vero E6 cells have a long track record with other high-consequence pathogens. The first human isolate of Andes virus, a hantavirus found in the Americas, was obtained through blind passages in Vero E6 cell monolayers.11Emerging Infectious Diseases. First Human Isolate of Hantavirus (Andes virus) in the Americas They are also commonly used for growing Crimean-Congo hemorrhagic fever virus, a tick-borne pathogen with a high fatality rate.12Virology Journal. Comparative characterization of Crimean-Congo hemorrhagic fever virus cell culture systems with application to propagation and titration methods And recent drug-screening work has used Vero E6 cells to test the compound probenecid against Ebola, Sudan, and Marburg viruses, finding that it inhibited replication of all three.13PubMed Central. Evaluation of Probenecid Against Filovirus Replication in Vero E6 Cells
The TMPRSS2 Problem and Engineered Upgrades
For all their advantages, standard Vero E6 cells have a significant blind spot when it comes to SARS-CoV-2 and similar viruses. In the human lung, SARS-CoV-2 primarily enters cells through a fast, surface-level pathway that depends on an enzyme called TMPRSS2. Vero E6 cells do not produce enough TMPRSS2, so the virus is forced to use a slower backup route through internal compartments called endosomes.14Genome Biology and Evolution. Systematic Exploration of SARS-CoV-2 Adaptation to Vero E6, Vero E6/TMPRSS2, and Calu-3 Cells The virus still gets in and replicates, but it is using a different door than it would in a real human infection. This matters because the entry route can influence which viral mutations are favored and how well drug candidates perform in lab tests.
Researchers addressed this by engineering Vero E6 cells that express TMPRSS2, and these modified cells proved to be highly susceptible to SARS-CoV-2 infection, making them better for isolating and growing the virus.15PubMed Central. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells Taking the approach even further, a cell line overexpressing both TMPRSS2 and human ACE2 (the receptor SARS-CoV-2 grabs onto to enter cells) showed a more than 20-fold increase in infectivity for several SARS-CoV-2 variants compared to standard Vero E6 cells.16Scientific Reports. Improved efficacy of SARS-CoV-2 isolation from COVID-19 clinical specimens using VeroE6 cells overexpressing TMPRSS2 and human ACE2 These upgraded cell lines became essential tools as new variants emerged during the pandemic, since some variants had evolved to rely more heavily on the TMPRSS2 pathway.
How Viruses Change When Grown in Vero E6 Cells
One of the most consequential lessons from the pandemic was how quickly SARS-CoV-2 mutates when grown in Vero E6 cells. The virus’s spike protein contains a furin cleavage site, a short stretch of amino acids that helps the virus enter human airway cells efficiently. But in Vero E6 cells, where the TMPRSS2 pathway is not available, that furin site actually becomes a disadvantage. Viruses that lost the furin cleavage site gained a fitness advantage in Vero E6 cells and quickly dominated lab cultures.17PubMed Central. Loss of Furin Cleavage Site Attenuates SARS-CoV-2 Pathogenesis The problem was that these mutant viruses, while thriving in the lab dish, were weakened in human airway tissue, because the furin site is important for infecting real lungs.
This adaptation happens surprisingly fast. Comparison studies found that SARS-CoV-2 evolved more rapidly and diversely in Vero E6 cells than in primary human airway epithelial cells, and isolates that lost the furin cleavage site during Vero E6 passage showed markedly reduced ability to grow in human-like cell cultures afterward.18PubMed Central. Comparison of SARS-CoV-2 Evolution in Paediatric Primary Airway Epithelial Cell Cultures Compared with Vero-Derived Cell Lines For researchers, this means that virus stocks prepared in Vero E6 cells need careful genetic monitoring. A virus that has been passaged too many times may no longer behave like the virus circulating in human populations, which can skew the results of drug tests, neutralization assays, and animal studies.
The furin cleavage site issue is the best-known example, but it is part of a broader phenomenon. Any time you grow a virus in a cell line that does not perfectly mimic the virus’s natural host cells, the virus can adapt to that artificial environment. Researchers manage this by keeping passage numbers low, sequencing virus stocks before experiments, and increasingly using the TMPRSS2-expressing versions of Vero E6 cells to reduce the selective pressure that drives furin site loss.
Vero Cells in Vaccine Manufacturing
Outside of research, Vero cells hold a unique position in vaccine production. They were the first continuous cell line approved by the World Health Organization for manufacturing human vaccines, and they remain the most widely accepted cell line by regulatory authorities for this purpose.19PubMed Central. Vero cell upstream bioprocess development for the production of viral vectors and vaccines Vaccines for polio and rabies have been produced in Vero cells for over 30 years.20PubMed. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines More recently, Vero cells have been used to produce vaccines against other viruses, and inactivated COVID-19 vaccines manufactured in some countries relied on Vero cell-based platforms.
Historically, one concern about using continuous cell lines for vaccine production was the worry that cells which divide indefinitely might have properties related to cancer, potentially posing a theoretical safety risk. Improved screening technologies have largely addressed those fears, and regulatory acceptance has grown steadily.20PubMed. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines Vaccine manufacturers must also test for adventitious agents, meaning unintended viral contaminants that could theoretically be present in cell banks or biological products. These testing methods, some dating to the mid-twentieth century, undergo periodic evaluation to make sure they remain sensitive enough.21PubMed Central. Systematic evaluation of in vitro and in vivo adventitious virus assays for the detection of viral contamination of cell banks and biological products
Scaling Up With Suspension Culture
A practical headache with Vero cells is that they are anchorage-dependent: they need to stick to a surface to grow. In a research lab, this is no problem; you grow them in flat flasks or on coated beads. But at manufacturing scale, providing enough surface area for billions of cells is labor-intensive and expensive.22PubMed. Development of suspension adapted Vero cell culture process technology for production of viral vaccines Adapting Vero cells to grow in suspension, floating freely in a liquid medium like bacteria in a fermenter, would dramatically simplify scale-up and cut production costs.
Recent work has made real progress on this front. A 2025 study characterizing suspension-adapted Vero cells found that they produced comparable or better yields of multiple viruses compared to traditional adherent cultures. For poliovirus serotype 3, suspension cells produced roughly 30% more vaccine antigen per unit volume. For yellow fever virus, the increase was about 150%, and for respiratory syncytial virus, the improvement was around 142%.23npj Vaccines. Characterization of a suspension Vero cell line for viral vaccine production If these results translate to full-scale manufacturing, suspension Vero cells could become a broadly useful platform for producing a range of viral vaccines more efficiently.
When Vero E6 Cells Are the Wrong Choice
Despite their versatility, Vero E6 cells are not suitable for every experiment. Any study that depends on intact interferon signaling cannot use them, since that pathway is genetically deleted. Research into how the innate immune system detects and responds to viral infection requires cell types that still have functional interferon genes, such as primary human cells or specialized immune cell lines.
For SARS-CoV-2 specifically, the culture-adaptation problem described earlier means that any experiment where the virus needs to closely resemble what circulates in people must be designed carefully. Using primary human airway epithelial cells, which express TMPRSS2 and closely mimic the lining of the respiratory tract, provides a more physiologically relevant system. The trade-off is that primary cells are harder to obtain, more expensive, and less standardized than an immortal cell line you can keep growing indefinitely.
There are also viruses that simply do not grow well in Vero cells. Not every pathogen finds the right receptors or conditions on Vero E6 surfaces. When researchers encounter a new virus that fails to replicate in standard cell lines, they often try a panel of different cell types before finding one that works. Vero E6 is usually on that panel, but it does not always win.
Why Researchers Keep Coming Back
Even with their limitations, Vero E6 cells persist as a default choice in virology for practical reasons that go beyond any single biological feature. They grow fast and reliably. They are well-characterized at the genomic level, which means researchers know what they are working with. They are accepted by regulatory agencies for vaccine production. And the sheer volume of published work done in Vero E6 cells means that any new experiment can be compared against a vast body of existing literature. When a lab reports that a drug blocks viral replication in Vero E6 cells, other labs around the world can replicate that experiment using the same cell line from the same repository, which is a kind of standardization that is hard to achieve with primary human tissue samples that vary from person to person. The cells have their quirks, and experienced virologists know exactly where those quirks matter and where they do not.